Dimericon Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $8.7M

  • Investors
  • 5

Dimericon Therapeutics General Information

Description

Developer of precision oncology therapeutics designed to target intracellular protein interactions using crosslinked helix dimer drug modalities. The company develops a discovery and drug development platform that translates metastable conformations of intrinsically disordered proteins into crosslinked helix dimer therapeutics and advances a portfolio of oncology programs targeting synthetic lethality pathways and oncogenic drivers such as apoptosis regulation and pan-Ras signaling, enabling pharmaceutical and biotechnology stakeholders to pursue new therapeutic approaches for genetically defined cancer populations with limited treatment options.

Contact Information

Website
www.dimericon.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Bachtobelstrasse 5
  • Horgen
  • 8810 Zurich
  • Switzerland
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • Bachtobelstrasse 5
  • Horgen
  • 8810 Zurich
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dimericon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 01-May-2023 $8.7M Completed Startup
To view Dimericon Therapeutics’s complete valuation and funding history, request access »

Dimericon Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preferance Shares
Preferance Shares
To view Dimericon Therapeutics’s complete cap table history, request access »

Dimericon Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
BioMedPartners Venture Capital Minority
CARMA FUND Management Venture Capital Minority
High-Tech Gründerfonds Venture Capital Minority
Therapy Acceleration Program (TAP) Not-For-Profit Venture Capital Minority
To view Dimericon Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Dimericon Therapeutics FAQs

  • When was Dimericon Therapeutics founded?

    Dimericon Therapeutics was founded in 2021.

  • Where is Dimericon Therapeutics headquartered?

    Dimericon Therapeutics is headquartered in Zurich, Switzerland.

  • What industry is Dimericon Therapeutics in?

    Dimericon Therapeutics’s primary industry is Biotechnology.

  • Is Dimericon Therapeutics a private or public company?

    Dimericon Therapeutics is a Private company.

  • What is the current valuation of Dimericon Therapeutics?

    The current valuation of Dimericon Therapeutics is .

  • What is Dimericon Therapeutics’s current revenue?

    The current revenue for Dimericon Therapeutics is .

  • How much funding has Dimericon Therapeutics raised over time?

    Dimericon Therapeutics has raised $8.7M.

  • Who are Dimericon Therapeutics’s investors?

    AbbVie Ventures, BioMedPartners, CARMA FUND Management, High-Tech Gründerfonds, and Therapy Acceleration Program (TAP) have invested in Dimericon Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process